Scientists develop new vaccine for Bundibugyo Ebola strain in DRC
Compare the reporting
Significant discrepancy in reported death toll and focus of the event.
Open the listed sources to review each publisher’s original wording.
Story essentials
Prof Teresa Lambe, Oxford Vaccine Group
Congo (DRC)
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRead next
Prioritized by shared people, places, and events.
Oxford University begins clinical trials for Bundibugyo Ebola vaccine
Oxford University has administered the first dose of a vaccine targeting the Bundibugyo strain of Ebola. The outbreak in DRC and Uganda has caused over 1,270 deaths and nearly 3,000 infections since May. The vaccine candidate was developed in eight weeks using technology similar to the AstraZeneca Covid-19 vaccine. WHO warns that the actual number of cases could be twice as high due to conflict-related access issues.
Related book
The Hot Zone: The Terrifying True Story of the Origins of the Ebola Virus
Author: Richard Preston
This classic work provides a gripping and scientifically grounded account of the emergence of filoviruses like Ebola, offering essential context on the nature of viral outbreaks and the immense challenges involved in containment and vaccine development.
As an Amazon Associate, COMPAMIR earns from qualifying purchases.